To investigate the impact of patiromer on serum potassium level and its ability to enable specified target doses of renin-angiotensin-aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF).

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial / Butler, J., Anker, S.D., Lund, L.H., Coats, A.J.S., Filippatos, G., Siddiqi, T.J., Friede, T., Fabien, V., Kosiborod, M., Metra, M., Piña, I.L., Pinto, F., Rossignol, P., Van Der Meer, P., Bahit, C., Belohlavek, J., Böhm, M., Brugts, J.J., Cleland, J.G., Ezekowitz, J., et al.. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - (2022). [10.1093/eurheartj/ehac401]

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial

Metra, Marco;
2022-01-01

Abstract

To investigate the impact of patiromer on serum potassium level and its ability to enable specified target doses of renin-angiotensin-aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF).
2022
Heart failure with reduced ejection fraction
Hyperkalemia
Patiromer
Potassium-binding polymer
renin-angiotensin-aldosterone system inhibitors (RAASi)
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/192949
Citazioni
  • ???jsp.display-item.citation.pmc??? 85
  • Scopus 185
  • ???jsp.display-item.citation.isi??? 169
social impact